'''Product Recall and Effects''': The Epinephrine auto-injection devices made by Sanofi SA currently on the market in the U.S. and Canada were voluntarily recalled on October 28, 2015.<ref>{{cite web|url=http://www.cbc.ca/news/health/allerject-epinephrine-auto-injectors-recalled-by-drugmaker-sanofi-1.3293765|title=All Allerject epinephrine auto-injectors recalled|publisher=}}</ref><ref>http://www.allerject.ca/Common/docs/en/Sanofi-Canada-Issues-Voluntary-Recall-of-Allerject.pdf</ref>  The reason stated by Sanofi was that the products have been found to potentially have inaccurate dosage delivery, which may include failure to deliver drug.<ref name="auvi-q.com">{{cite web|url=https://www.auvi-q.com/|title=Auvi-Q® (epinephrine injection, USP)|publisher=}}</ref><ref name="fda.gov">{{cite web|url=http://www.fda.gov/Safety/Recalls/ucm469980.htm|title=Recalls, Market Withdrawals, & Safety Alerts - UPDATED: Sanofi US Issues Voluntary Nationwide Recall of All Auvi-Q® Due to Potential Inaccurate Dosage Delivery|first=Office of Regulatory Affairs, Office of the|last=Commissioner|website=www.fda.gov|accessdate=23 May 2017}}</ref>

 
As of the summer of 2013, Sanofi was in a race with [[Amgen]] and [[Pfizer]] to win approval for a [[PCSK9 inhibitor|drug that inhibits PCSK9]], a protein that slows the clearance of [[low-density lipoprotein]] (LDL) cholesterol - the form of cholesterol that leads to heart attacks.<ref>Gina Kolata for the New York Times. 9 July 2013 [https://www.nytimes.com/2013/07/10/health/rare-mutation-prompts-race-for-cholesterol-drug.html?partner=rss&emc=rss&pagewanted=all Rare Mutation Ignites Race for Cholesterol Drug]</ref>  Sanofi's drug was discovered by [[Regeneron]] and is called [[alirocumab]].<ref>[http://www.regeneron.com/regn727 Alirocumab on Regeneron's website] {{webarchive |url=https://web.archive.org/web/20120416102019/http://www.regeneron.com/regn727 |date=16 April 2012 }}</ref>  An FDA warning in March 2014 about possible cognitive adverse effects of PCSK9 inhibition threw the competition into disarray, as the FDA asked companies to include neurocognitive testing into their [[Phase III]] clinical trials.<ref>John Carroll for FierceBiotech 7 March 2014 [http://www.fiercebiotech.com/story/regeneron-sanofi-and-amgen-shares-suffer-fdas-frets-about-pcsk9-drug/2014-03-07 UPDATED: Regeneron, Sanofi and Amgen shares suffer on FDA's frets about PCSK9 class]</ref>
